NCT05854823招募中不适用
De-escalation of Postoperative Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma With Pathological Complete Response/Major Pathological Response: A Single-arm, Prospective Phase II Clinical Study
Fifth Affiliated Hospital, Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2023年4月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Disease Free Survival (DFS)
研究概览
简要总结
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of de-escalation of postoperative radiotherapy in locally advanced head and neck squamous cell carcinoma with pathological complete response/major pathological response to neoadjuvant therapy. The eligible patients are scheduled to administered postoperative radiotherapy, PTV 50Gy/25F, instead of the standard dose of 60Gy. The overall primary study hypothesis is that reducing the dose of postoperative radiotherapy in the specific population does not affect DFS but significantly reduces treatment related adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Untreated, histologically confirmed head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx or larynx), staging T3-4N0M0 or T1-4N1-3M0, III-IVB, according to the eighth edition of the AJCC staging system; within 6 weeks after receiving neoadjuvant therapy and radical surgery.
- •Pathological evaluation of surgical specimens was pCR (pathologic complete response, no viable tumor cells) or MPR (Major pathologic response, residual viable tumor cells≤10%).
- •Negative surgical margin.
- •No extranodal extension.
- •Aged ≥ 18 years and ≤ 70 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Life expectancy of more than 6 months.
- •Adequate organ function, based on meeting all of the following criteria (no blood components and cytologic growth factors were received within 14 days prior to the test):
- •Hemoglobin ≥ 75 g/L; absolute neutrophil count ≥ 1.5 × 10^9/L; and platelet count ≥ 100 × 10^9/L;
- •Serum albumin ≥ 25 g/L;
- •Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN;
- •Serum creatinine ≤ 1.5 × ULN;
- •Activated partial clotting enzyme time and international standardized ratio (INR) ≤ 1.5 × ULN (Patients on stable doses of anticoagulant therapy such as low molecular weight heparin or warfarin with INR within the expected treatment range of anticoagulants can be screened ).
- •Women of childbearing age should agree to the use of contraception (e.g., intrauterine devices, birth control pills, or condoms) during treatment and for 3 months thereafter.
- •The regimen of neoadjuvant therapy can be determined by the clinician.
- •Subjects voluntarily join the study and sign an informed consent form, with good compliance.
排除标准
- •Pregnant or lactating women.
- •A history of other malignant tumors within the previous 5 years or at the time of enrollment, except for cured skin basal cell carcinoma and cervical in situ cancer, as well as thyroid papilloma.
- •Neoadjuvant therapy or radical surgery was not completed.
- •Recurrence or distant metastasis occurred before postoperative radiotherapy.
- •There are contraindications for radiotherapy, chemotherapy, immunotherapy and targeted therapy.
- •Uncontrolled cardiac clinical symptoms or diseases.
- •Serious infections.
- •A history of immunodeficiency, including HIV-positive status or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and bone marrow transplantation.
- •Patients with active tuberculosis infection found by history or CT examination, or patients with active tuberculosis infection history within 1 year prior to enrollment, or patients with active tuberculosis infection history before 1 year without formal treatment.
- •Active hepatitis B (HBV DNA ≥ 2,000 IU/mL or 10,000 copies/mL) or hepatitis C (positive HCV antibody test and HCV RNA above the lower limit of detection).
- •Known history of psychotropic drug abuse, alcoholism and drug use.
- •Not suitable for inclusion, as judged by the investigator.
结局指标
主要结局
Disease Free Survival (DFS)
时间窗: from the first day of treatment to the follow up of 2 years
2-year disease free survival rate
次要结局
- Overall Survival (OS)(from the first day of treatment to the follow up of 2 years)
- EORTC QLQ-C30(from 1 week before treatment to the follow up of 2 years)
- EORTC HN35(from 1 week before treatment to the follow up of 2 years)
- Local Relapse Free Survival (LRFS)(from the first day of treatment to the follow up of 2 years)
- Distant Metastasis Free Survival (DMFS)(from the first day of treatment to the follow up of 2 years)
- RTOG/EORTC late radiation morbidity scoring scheme(from 1 week before treatment to the follow up of 2 years)
研究者
Yingpeng Peng
Director
Fifth Affiliated Hospital, Sun Yat-Sen University
研究点 (1)
Loading locations...
相似试验
招募中
2 期
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the LarynxSquamous Cell Carcinoma of the HypopharynxSquamous Cell Carcinoma of the OropharynxNCT06030440University of Erlangen-Nürnberg Medical School508
招募中
不适用
Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell CarcinomaHead and Neck CarcinomaNCT05650034National Cancer Institute, Egypt57
招募中
2 期
Anlotinib and Radiotherapy in Resectable Soft Tissue SarcomaSoft Tissue SarcomaHigh Risk of RecurrenceAnlotinibRadiotherapyNCT05602415Ruijin Hospital41
已完成
不适用
Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Radiation Care® GelRadiation DermatitisNCT04995328China Medical University Hospital23
进行中（未招募）
不适用
Intraoperative Radiation Therapy for Resectable Pancreatic CancerResectable Pancreatic CancerNCT05181488Yona Cho80